Opiant Pharmaceuticals, Inc.
OPNT · NASDAQ
9/30/2022 | 6/30/2022 | 3/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $173,874 | $2,326 | $2,193 | $13,036 |
| % Growth | 7,375.2% | 6.1% | -83.2% | – |
| Cost of Goods Sold | $0 | $517 | $426 | $2,921 |
| Gross Profit | $173,874 | $1,809 | $1,767 | $10,115 |
| % Margin | 100% | 77.8% | 80.6% | 77.6% |
| R&D Expenses | $4,134 | $7,916 | $8,823 | $4,714 |
| G&A Expenses | $3,073 | $4,011 | $4,332 | $3,394 |
| SG&A Expenses | $5,670 | $6,826 | $7,009 | $4,890 |
| Sales & Mktg Exp. | $2,597 | $2,816 | $2,677 | $1,496 |
| Other Operating Expenses | -$174 | -$1,568 | -$2,277 | $9,072,729 |
| Operating Expenses | $9,630 | $13,175 | $13,555 | $8,841 |
| Operating Income | -$9,630 | -$11,365 | -$11,788 | $1,279 |
| % Margin | -5.5% | -488.6% | -537.5% | 9.8% |
| Other Income/Exp. Net | -$48 | $0 | $16 | -$2,121,625 |
| Pre-Tax Income | -$9,908 | -$11,704 | -$12,188 | $777 |
| Tax Expense | $9 | $32 | $400 | $24 |
| Net Income | -$9,917 | -$11,737 | -$12,588 | $752 |
| % Margin | -5.7% | -504.6% | -574% | 5.8% |
| EPS | -1.93 | -2.31 | -2.51 | 0.17 |
| % Growth | 16.5% | 8% | -1,576.5% | – |
| EPS Diluted | -1.93 | -2.31 | -2.51 | 0.13 |
| Weighted Avg Shares Out | 5,138 | 5,088 | 5,015 | 4,456 |
| Weighted Avg Shares Out Dil | 5,138 | 5,088 | 5,015 | 5,920 |
| Supplemental Information | – | – | – | – |
| Interest Income | $160 | $63 | $5 | $1 |
| Interest Expense | $391 | $401 | $421 | $503 |
| Depreciation & Amortization | $12 | $8 | $8 | $583 |
| EBITDA | -$9,458 | -$11,295 | -$11,775 | $1,862 |
| % Margin | -5.4% | -485.6% | -536.9% | 14.3% |